New Delhi, Jul 24 (PTI) AstraZeneca Pharma India on Monday said it has received approval from the Drugs Controller General of India to import heart failure treatment drug Dapagliflozin tablets.

Also Read | Hyderabad Shocker: Man Throws Himself Under Moving Bus, Dies; Chilling Video of Suicide Goes Viral.

The company has received permission from the DCGI to import pharmaceutical formulations of a new drug for sale, the drug firm said in a regulatory filing.

Also Read | Twitter Losing Blue Bird? Elon Musk Rebranding Twitter to 'X.com' with an X Logo Replacing the Iconic Bird Emblem.

Dapagliflozin tablets are indicated for the treatment of heart failure in adults, it added.

The receipt of this permission paves the way for the launch of the product in India for the specified indication, subject to the receipt of related statutory approvals and licenses, it said.

Shares of the company on Monday ended 0.86 per cent down at Rs 3,769.40 apiece on the BSE.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)